Journal of Clinical Oncology
Articles in this Issue
Pretreatment serum sodium as a prognostic factor for patients with advanced esophageal cancer receiving immunotherapy or immunotherapy combined with radiotherapy.
e16027 Background: Existing studies have shown that pretreatment serum sodium levels are associated with the prognosis of various cancers. However, the re...
Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent Bruton tyrosine kinase inhibitors (cBTKi): A real-world study.
e23334 Background: Covalent Bruton tyrosine kinase inhibitors (cBTKi) are a mainstay of first-line (1L) therapy in CLL/SLL. However, there are concerns ab...
Effect of clonal competition model of PDAC liver metastasis on a pan-carcinoma gene signature of metastatic potential.
e16452 Background: Liver metastasis is a leading cause of death amongst localized pancreatic ductal adenocarcinoma (PDAC) patients following surgical rese...
Real-world effectiveness and safety of ondansetron oral soluble film for the prevention of chemotherapy-induced nausea and vomiting.
e24079 Background: Chemotherapy-induced nausea and vomiting (CINV) are significant adverse effects that compromise patient adherence and quality of life....
Survival outcomes for ovarian cancer patients in the post–poly ADP-ribose polymerase inhibitor (PARPi) era in the US.
5586 Background: PARPi introduction in clinical practice has led to major changes in the therapeutic landscape for ovarian cancer (OC) 1...
Frequency of RAS family gene mutations in metastatic solid tumors in Venezuela: Experience at a large academic center.
e13538 Background: Understanding the molecular profile of cancer-associated genes is crucial in oncology, as it informs targeted therapies and improves pa...
Gastrointestinal adverse event in patients with and without pre-existing inflammatory bowel disease.
e24084 Background: Immune checkpoint inhibitors (ICI) enhance immune function and may cause gastrointestinal adverse events (GIAEs), such as immune-mediat...
Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer.
TPS1136 Background: Metastatic breast cancer is almost always fatal. Objectives: Primary: To evaluate the safety of BC1 cell line immunotherapy in patient...
Real-world efficacy of trifluridine/tipiracil and bevacizumab combination according to baseline prognostic factors: The BeTAS study.
3578 Background: The Sunlight Trial demonstrated that trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) significantly improved Overall Survival (OS)...
Predicting therapeutic response in stomach adenocarcinoma by integrating H&E and RNA-seq using deep learning.
e16088 Background: Recent breakthroughs in computational pathology have transformed how we analyze histopathology images, making it possible to predict cl...
A multimodal analysis of CT radiomics and clinical variables in predicting immunotherapy response for NSCLC.
e20566 Background: Immunotherapy (IO) is a viable therapeutic approach for non-small cell lung cancer (NSCLC). Despite the significant survival benefit of...
A novel magnetic bead-based cfDNA extraction method for advanced ctDNA marker discovery and methylation profiling.
3051 Background: Cell-free DNA (cfDNA) extraction and circulating tumor DNA (ctDNA) enrichment are critical for liquid biopsy-based cancer diagnostics. Ho...
Impact of obesity on CAR t-cell therapy outcomes in diffuse large B-cell lymphoma.
e19017 Background: Obesity has been associated with poorer outcomes in conventional cancer therapies. However, its impact on Chimeric Antigen Receptor (CA...
Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data.
12027 Background: Cardiovascular disease (CVD) is a leading cause mortality in cancer patients. Obesity and type 2 diabete...
Understanding the molecular landscape of rare tumors through the CCDI-COG Molecular Characterization Initiative.
10012 Background: Through collaboration with the National Cancer Institute as part of the Childhood Cancer Data Initiative, the Children’s Oncology Group...
Patients’ digital health needs and the potential impact of a digital health navigator on the oncology care team: Provider and patient perspectives.
e13712 Background: Patient use of digital health tools (e.g., patient portals) is associated with improved patient retention, engagement, satisfaction, me...
Initiation of high dose chemotherapy at rising tumor markers compared with radiographic progression in patients with relapsed germ-cell tumors (GCT).
5033 Background: Patients with GCT who relapse after first-line therapy can be cured with salvage high-dose chemotherapy (HDCT). We evaluate the outcomes...
Efficacy profile of pembrolizumab for primary pulmonary NUT carcinoma: A systematic review and meta-analysis.
8586 Background: Primary pulmonary NUT carcinoma is an exceedingly rare and aggressive malignancy characterized by chromosomal rearrangements involving th...
Impact of radionuclide therapy on survival outcomes for de novo metastatic gastroenteropancreatic neuroendocrine tumors: A population-based cohort study.
4144 Background: De novo metastatic gastroenteropancreatic neuroendocrine tumors (dmGEP-NETs) are difficult to treat without the option of radical surgery...
Proteomic signatures of biofluid-derived extracellular vesicles for benign and malignant ovarian tumor differentiation, prognosis, and chemotherapy response prediction.
e17562 Background: Small extracellular vesicles (sEVs) are nano-sized particles that reflect the pathological state of their origin cells and serve as pro...
Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis.
3148 Background: NTRK gene fusions are oncogenic drivers in various tumor types. Larotrectinib (laro)...
Evaluation of the combination of lurbinectedin and atezolizumab in a humanized mouse model.
e14614 Background: Lurbinectedin, a synthetic ectenaiscidin approved by the FDA in 2020 for the treatment of extensive small cell lung cancer (SCLC) after...
Early genetic mutations associated with pathological complete response in triple-negative breast cancer and prognostic implications.
e13132 Background: Triple-negative breast cancer (TNBC) with early-stage disease is typically treated with neoadjuvant chemotherapy with curative intent....
Actionability of genomic alterations in the Molecular Screening and Therapeutics (MoST) program in New Zealand (NZ) depending on residence in NZ or Australia.
e13763 Background: The Australian-led MoST program (ACTRN12616000908437 ) expands access to comprehensive genomic profiling (CGP) for rare, advanced, and...
Increased racial and ethnic groups representation in clinical trials in a demographically diverse population.
e13782 Background: Florida has a diverse population, with Hispanics (of all races) becoming the largest subpopulation after White non-Hispanics. Cleveland...